Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
for Core Binding Factor Acute Myeloid Leukemia
Drug: Venetoclax
Sites in Creve Coeur, St Louis +63 more locations
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18 - 59
Code: NCT06917911·Phase 2·Recruiting·Listed Apr 2025